Scientists have developed an injection that turns muscle into a temporary drug factory, offering a potential new way to help the heart repair itself after a heart attack.
The RNA-based therapy aims to address one of cardiology’s most persistent challenges: the heart’s limited ability to regenerate after injury.
After a heart attack, restoring blood flow is often only part of the battle. Even when blocked arteries are reopened, the heart can suffer permanent damage because lost muscle cells do not naturally regrow.
Ke Cheng, the Alan L. Kaganov Professor of Biomedical Engineering at Columbia Engineering, explained that the heart is one of the least regenerative organs in the body, meaning its ability to repair itself is extremely limited.
This limitation is a major reason many survivors later develop heart failure. Researchers are now exploring a different strategy, one that not only prevents further damage but actively promotes healing.
In a study published in Science, Cheng and his colleagues describe an experimental therapy that turns the body into its own drug producer.
Instead of delivering medicine directly to the heart, the approach uses RNA to instruct other tissues to produce a healing molecule that becomes active only once it reaches the heart.
“You don’t have to open the chest or send a wire to the heart to deliver this drug. In principle, all the clinician needs to do is inject the particles into the arm,” Cheng said.
Study co-author Torsten Vahl, a cardiologist, noted that the injection could address a long-standing gap in care, as many patients with severe heart damage are left with limited treatment options and often go on to develop heart failure.
In preclinical studies, a single injection reduced scar tissue and improved heart function in both small and large animals. These findings suggest a potential path toward treatments that are not only effective but also simpler and more accessible than procedures such as transplants or cell-based therapies.
Delivering drugs to the heart in a lasting and minimally invasive way has long been a challenge. Organs like the liver and lungs can naturally absorb certain drugs due to their structure and blood flow, but the heart lacks this advantage, making targeted delivery more difficult.
To overcome this, the researchers developed a two-step strategy. Instead of delivering the drug directly to the heart, they first create an inactive precursor in skeletal muscle, which is later activated within the heart.
When injected into the muscle in the arm or thigh, cells begin producing pro-atrial natriuretic peptide (ANP). This inactive molecule then travels through the bloodstream until it reaches the heart, where it becomes active.
